Full text
PDFPage 207
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1979 Jul;18(1):1–24. doi: 10.2165/00003495-197918010-00001. [DOI] [PubMed] [Google Scholar]
- Chouinard G., Jones B. D., Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978 Nov;135(11):1409–1410. doi: 10.1176/ajp.135.11.1409. [DOI] [PubMed] [Google Scholar]
- Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science. 1977 Aug 5;197(4303):596–598. doi: 10.1126/science.877576. [DOI] [PubMed] [Google Scholar]
- Grof P., Saxena B., Daigle L., Mahutte G. Dopaminergic agonist nomifensine compared with amitriptyline: a double-blind clinical trial in acute primary depressions. Br J Clin Pharmacol. 1977;4(Suppl 2):221S–225S. doi: 10.1111/j.1365-2125.1977.tb05756.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Manno B. R., Manno J. E. Toxicology of ipecac: a review. Clin Toxicol. 1977;10(2):221–242. doi: 10.3109/15563657708987968. [DOI] [PubMed] [Google Scholar]
- Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367:69–93. doi: 10.1111/j.1365-201x.1971.tb11000.x. [DOI] [PubMed] [Google Scholar]